# THPO

## Overview
The THPO gene encodes thrombopoietin, a glycoprotein hormone that plays a pivotal role in hematopoiesis, particularly in the regulation of platelet production. Thrombopoietin is classified as a cytokine and functions by binding to the c-MPL receptor on hematopoietic stem cells, promoting their proliferation and differentiation into megakaryocytes, which are precursors to platelets (Kaushansky1994Promotion; Hitchcock2014Thrombopoietin). The THPO gene is primarily expressed in the liver, with its protein product being released into the bloodstream to exert its effects in the bone marrow (Decker2018Hepatic). The regulation of thrombopoietin levels is critical for maintaining hematopoietic balance, and dysregulation can lead to various hematological disorders, including thrombocytopenia and thrombocythemia (Liu2008A; Capaci2022Defective). Understanding the structure and function of the THPO gene and its encoded protein is essential for elucidating the mechanisms underlying these conditions and developing potential therapeutic interventions.

## Structure
The human thrombopoietin (THPO) protein is a polypeptide consisting of 353 amino acids, including a 21 amino acid secretory leader sequence. The mature protein is divided into two main domains: the amino-terminal domain, which is homologous to erythropoietin (EPO) and binds to the c-MPL receptor, and the carboxyl-terminal domain, which is unique to THPO. This carboxyl-terminal domain is responsible for prolonging the hormone's circulatory half-life and aiding in the proper folding of the polypeptide. It is modified with multiple sites of both N- and O-linked carbohydrates, which are common post-translational modifications (Hitchcock2014Thrombopoietin).

Specific residues within the THPO structure, such as Arg10, Lys14, Arg17, His133, Gln132, Lys138, and Phe141, are crucial for binding to the c-MPL receptor. A mutation at Arg17 has been associated with congenital thrombocytopenia and aplastic anemia, highlighting the importance of these residues in receptor interaction (Hitchcock2014Thrombopoietin).

The THPO gene has an unusual 5' untranslated region, with translation initiating at the eighth ATG codon, leading to inefficient translation under normal circumstances. Mutations in non-coding sequences can enhance translation efficiency, potentially causing thrombocytosis (Hitchcock2014Thrombopoietin).

## Function
Thrombopoietin (THPO) is a crucial cytokine involved in the regulation of hematopoietic stem cells (HSCs) and platelet production. It primarily functions by binding to its receptor, c-Mpl, on the surface of HSCs, promoting their survival, proliferation, and differentiation into megakaryocytes, which are essential for platelet production (Kaushansky1994Promotion; Hitchcock2014Thrombopoietin). THPO is predominantly produced in the liver and, to a lesser extent, in the kidneys, and is released into the circulation to exert its effects in the bone marrow (Decker2018Hepatic; Hitchcock2021The).

In healthy human cells, THPO maintains the balance between HSC maintenance and differentiation, ensuring a steady supply of platelets and supporting hematopoietic health (Tsutsumi2023Structure). The signaling pathways activated by THPO include JAK/STAT, PI3K/AKT, and Raf-1/MAP kinase, which are crucial for cellular survival and proliferation (Hitchcock2014Thrombopoietin). The regulation of THPO levels is tightly controlled, with mechanisms such as the 'platelet sponging theory' where circulating THPO is bound and internalized by platelets, influencing its availability and activity (Hitchcock2021The). This regulation ensures that platelet production is responsive to physiological needs, maintaining homeostasis in the circulatory system.

## Clinical Significance
Mutations in the THPO gene, which encodes thrombopoietin, are associated with various hematological disorders. Congenital amegakaryocytic thrombocytopenia (CAMT) is a recessive disorder characterized by a severe reduction in megakaryocytes and platelets at birth, often progressing to bone marrow aplasia. CAMT can result from mutations in the THPO gene, such as the c.-323C>T mutation in the promoter region, which impairs the binding of transcription factors ETS1 and STAT4, leading to reduced THPO expression and low platelet counts (Capaci2022Defective).

Hereditary thrombocythemia, an autosomal dominant disorder, is linked to mutations in the THPO gene that lead to excessive platelet production. For instance, a G→C transversion in the splice donor site of intron 3 results in increased THPO mRNA translation and overproduction of thrombopoietin, causing elevated platelet counts and associated symptoms like hypertension and thrombosis (Liu2008A).

Additionally, a frameshift variant, THPO:c.388_389delAG, has been identified in patients with hereditary thrombocytopenia and is associated with a predisposition to myeloid neoplasms, such as myelodysplastic syndrome (Kwon2022Novel). These mutations highlight the critical role of THPO in maintaining normal platelet levels and its involvement in various hematological conditions.

## Interactions
Thrombopoietin (THPO) primarily interacts with the myeloproliferative leukemia virus oncogene (MPL) receptor, which is crucial for its role in hematopoiesis. The interaction between THPO and MPL involves two binding sites with different affinities, facilitating the formation of a signaling complex. The high-affinity site involves interactions between THPO and MPL domains D1 and D2, while the low-affinity site also involves interactions with these domains, although attempts to measure the low-affinity binding were unsuccessful (Tsutsumi2023Structure). 

THPO binding to MPL induces receptor dimerization, activating associated kinases such as JAK2 and TYK2, which trigger downstream signaling pathways involving STAT proteins and other adaptors (Plo2017Genetic). This interaction is essential for the activation of signaling pathways like JAK/STAT, ERK/AKT, and CREB, which are involved in cell proliferation, differentiation, and survival (Tsutsumi2023Structure). 

Mutations in THPO can affect its interaction with MPL, leading to altered signaling and hematopoietic outcomes. For instance, specific THPO variants like TPO-K35A and TPO-R119E have been shown to modulate the efficacy of MPL-JAK2 dimer formation, impacting the JAK/STAT signaling pathway (Tsutsumi2023Structure).


## References


[1. (Hitchcock2014Thrombopoietin) Ian S. Hitchcock and Kenneth Kaushansky. Thrombopoietin from beginning to end. British Journal of Haematology, 165(2):259–268, February 2014. URL: http://dx.doi.org/10.1111/bjh.12772, doi:10.1111/bjh.12772. This article has 158 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.12772)

[2. (Decker2018Hepatic) Matthew Decker, Juliana Leslie, Qingxue Liu, and Lei Ding. Hepatic thrombopoietin is required for bone marrow hematopoietic stem cell maintenance. Science, 360(6384):106–110, April 2018. URL: http://dx.doi.org/10.1126/science.aap8861, doi:10.1126/science.aap8861. This article has 87 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.aap8861)

[3. (Tsutsumi2023Structure) Naotaka Tsutsumi, Zahra Masoumi, Sophie C. James, Julie A. Tucker, Hauke Winkelmann, William Grey, Lora K. Picton, Lucie Moss, Steven C. Wilson, Nathanael A. Caveney, Kevin M. Jude, Cornelius Gati, Jacob Piehler, Ian S. Hitchcock, and K. Christopher Garcia. Structure of the thrombopoietin-mpl receptor complex is a blueprint for biasing hematopoiesis. Cell, 186(19):4189-4203.e22, September 2023. URL: http://dx.doi.org/10.1016/j.cell.2023.07.037, doi:10.1016/j.cell.2023.07.037. This article has 9 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2023.07.037)

[4. (Liu2008A) K. Liu, R. Kralovics, Z. Rudzki, B. Grabowska, A. S. Buser, D. Olcaydu, H. Gisslinger, R. Tiedt, P. Frank, K. Okon, A. P.C. van der Maas, and R. C. Skoda. A de novo splice donor mutation in the thrombopoietin gene causes hereditary thrombocythemia in a polish family. Haematologica, 93(5):706–714, May 2008. URL: http://dx.doi.org/10.3324/haematol.11801, doi:10.3324/haematol.11801. This article has 37 citations.](https://doi.org/10.3324/haematol.11801)

[5. (Kwon2022Novel) Seok Ryun Kwon, Man Jin Kim, Young-eun Lee, Jiwon Yun, Da-jeong Jeong, Jae Hyeon Park, Sunghoon Kwon, and Dong Soon Lee. Novel thpo variant in hereditary thrombocytopenia: a potential candidate variant for predisposition to myeloid neoplasm. PLOS ONE, 17(12):e0271624, December 2022. URL: http://dx.doi.org/10.1371/journal.pone.0271624, doi:10.1371/journal.pone.0271624. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0271624)

[6. (Hitchcock2021The) Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae, and Julie A. Tucker. The thrombopoietin receptor: revisiting the master regulator of platelet production. Platelets, 32(6):770–778, June 2021. URL: http://dx.doi.org/10.1080/09537104.2021.1925102, doi:10.1080/09537104.2021.1925102. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/09537104.2021.1925102)

[7. (Plo2017Genetic) Isabelle Plo, Christine Bellanné-Chantelot, Matthieu Mosca, Stefania Mazzi, Caroline Marty, and William Vainchenker. Genetic alterations of the thrombopoietin/mpl/jak2 axis impacting megakaryopoiesis. Frontiers in Endocrinology, September 2017. URL: http://dx.doi.org/10.3389/fendo.2017.00234, doi:10.3389/fendo.2017.00234. This article has 38 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2017.00234)

[8. (Capaci2022Defective) Valeria Capaci, Etai Adam, Ifat Bar-Joseph, Michela Faleschini, Alessandro Pecci, and Anna Savoia. Defective binding of ets1 and stat4 due to a mutation in the promoter region of &lt;i&gt;thpo&lt;/i&gt; as a novel mechanism of congenital amegakaryocytic thrombocytopenia. Haematologica, 108(5):1385–1393, October 2022. URL: http://dx.doi.org/10.3324/haematol.2022.281392, doi:10.3324/haematol.2022.281392. This article has 4 citations.](https://doi.org/10.3324/haematol.2022.281392)

[9. (Kaushansky1994Promotion) Kenneth Kaushansky, Si Lok, Richard D. Holly, Virginia C. Broudy, Nancy Lin, Mason C. Bailey, John W. Forstrom, Michele M. Buddle, Pieter J. Oort, Fredrick S. Hagen, Gerald J. Roth, Thalia Papayannopoulou, and Donald C. Foster. Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin. Nature, 369(6481):568–571, June 1994. URL: http://dx.doi.org/10.1038/369568a0, doi:10.1038/369568a0. This article has 808 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/369568a0)